PRESSEMITTEILUNGEN

Paris (ots/PRNewswire) – Results from three separate European health economic analyses of the TRITON-TIMI 38 study showed that treatment with Efient(R) (prasugrel) compared with clopidogrel (Plavix(R)) reduced medical costs by lowering rehospitalisation rates and the need for repeat percutaneous coronary interventions (PCI), including stenting. The analyses, conducted in Germany, France and the UK, showed prasugrel to be a cost-effective treatment option for patients with acute coronary syndrome (ACS) undergoing PCI. These data were presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress in Paris.

The analyses showed that treatment with prasugrel compared with branded clopidogrel lowered medical costs due to the demonstrated reduction in the risk of thrombotic cardiovascular events following an initial PCI, including events during the initial hospitalisation as well as recurrent heart attacks, rehospitalisations and repeat stenting procedures, across several patient groups studied. The greater efficacy of prasugrel in TRITON-TIMI 38 resulted in reductions in the use of expensive healthcare resources such as intensive care unit expenses, rehospitalisations and stenting procedure costs.(1, 2, 3)

“These health economic analyses are important because the results provide the healthcare community with new data to help evaluate prasugrel as an appropriate and cost-effective antiplatelet therapy for patients with acute coronary syndrome undergoing angioplasty,” said Joerg Rustige, M.D., Medical Director Cardiovascular, Europe, Eli Lilly and Company. “We believe there is a need to provide innovative medications that improve patient outcomes and do not contribute to increased healthcare costs for patients and the healthcare system.”

“ACS is a life-threatening condition that is associated with a significant emotional and economic burden to patients,” said Thomas Portz, Ph.D., Head of Public Affairs, Daiichi Sankyo Europe, GmbH. “It is essential that effective new antiplatelet therapies with minimal drug budget impact to the healthcare system are available for ACS-PCI patients.”

German Analysis

An analysis of the TRITON-TIMI 38 health economic sub-study performed using German healthcare costs showed medical expenses over the 14.5-month trial period were lower with prasugrel compared with branded clopidogrel by euro 20 per patient in the population of patients who had no history of transient ischemic attack/stroke, weight>=60kg and were

Trackback URL

Acute Coronary Syndrome, Antiplatelet Therapy, Cardiovascular Events, Clopidogrel, Clopidogrel Plavix, Coronary Interventions, D Medical, Economic Analyses, Eli Lilly, Eli Lilly And Company, European Congress, European Health, Healthcare Community, Healthcare Resources, Intensive Care Unit, Lilly And Company, Outcomes Research, Patient Groups, Patient Outcomes, Pharmacoeconomics